Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of trilaciclib
NCT02243150Phase 1Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trilaciclib in myelosuppression (7 cohorts), sponsored by G1 Therapeutics, Inc. Primary endpoint: Adverse Events. Started Sep 2014; status: completed.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT02243150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243150.